BioDiem’s leading product is the Live Attenuated Influenza Virus (LAIV) technology, which has been used to develop a novel intranasal vaccine for seasonal and pandemic influenza. The technology is licensed to BioDiem by the Institute of Experimental Medicine in St Petersburg. The LAIV influenza vaccine can be produced using egg-based and cell-based manufacturing.  

The cell-based LAIV vaccine has completed first-in-human and proof-of-concept clinical trials in Europe as part of development for European registration. The cell-based LAIV vaccine technology is currently available for licence from BioDiem.

The egg-based LAIV vaccine technology is licensed to the World Health Organization for developing countries as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. This allows governmental and non-governmental organizations or private companies in developing countries to produce seasonal and pandemic vaccines in eggs. The egg-based LAIV vaccine has been launched in India as Nasovac™ for protection against H1N1 influenza. The egg-based LAIV vaccine technology is currently available for licence from BioDiem for non-developing country markets.

BioDiem is also investigating use of its proprietary LAIV technology as a viral vector for design of vaccines for disease prevention and treatment.

BioDiem’s business model is to generate income from partnerships including with other vaccine development companies through existing and new licences to its LAIV vaccine and other technologies while pursuing development of its own vaccines. BioDiem will also consider the acquisition of complementary technologies.

BioDiem’s business model has already proven successful with payments having been received for both the cell-based LAIV and egg-based LAIV technologies.